In vitro antibiotic susceptibilities of ocular bacteria isolates from the cornea and conjunctiva to moxifloxacin, gatifloxacin and other fluoroquinolones

Arquivos Brasileiros de Oftalmologia

Volumn 67, Issue 6, 2004, Pages 883-886

  Höfling Lima, Ana Luisa ^a   Belfort Jr , Rubens ^a   Moeller, Cecília Tobias Aguiar ^a   Branco, Bruno Castelo ^a   De Sousa, Luciene Barbosa ^a   De Freitas, Denise ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bacterial; Conjunctiva microbiology; Cornea microbiology; Drug resistance; Eye infections; Microbial; Microbial sensitivity tests; Quinolones

Indexed keywords

EID: 39049139023     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492004000600007     Document Type: Article

References (23)

1. Cokingtin CD, Hyndiuk RA. Insights from experimental data on ciprofloxacin in the treatment of bacterial keratitis and ocular infections. Am J Ophthalmol. 1991;112(4 Suppl):25S-8.
2. Limberg MB. A review of bacterial keratitis and bacterial conjunctivitis. Am J Ophthalmol. 1991;112(Suppl. 4):2S-9.
3. Garg P, Sharma S, Rao GN. Ciprofloxacin-resistant Pseudomonas keratitis. Ophthalmology. 1999;106(7):1319-1323
4. Leibowitz HM. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. Am J Ophthalmol. 1991;112(Suppl. 4):34S-47.
5. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999;106(7):1313-1318
6. Castillo A, Benitez del Castillo JM, Toledano N, Diaz-Valle D, Sayagues O, Garcia-Sanches J. Deposits of topical norfloxacin in the treatment of bacterial keratitis. Cornea. 1997;16(4):420-423
7. Bower KS, Kowalski RP, Gordon YJ. Fluoroquinolones in the treatment of bacterial keratitis. Am J Ophthalmol. 1996;121(6):712-715
8. Ofloxacin monotherapy for the primary treatment of microbial keratitis: a double-masked, randomized, controlled trial with conventional dual therapy. The Ofloxacin Study Group. Ophthalmology. 1997;104(11):1902-1909
9. Ogawa GS, Hyndiuk RA. The fluoroquinolones: new antibiotics in ophthalmology. Int Ophthalmol Clin. 1993;33(4):59-68.
10. Serdarevic ON. Role of the fluoroquinolones in ophthalmology. Int Ophthalmol Clin. 1993;33(1):163-178
11. O'Brien TP, Maguire MG, Fink NE, Alfonso E; McDonnell P. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group. Arch Ophthalmol. 1995;113(10):1257-1265
12. Donnenfeld ED, Schrier A, Perry HD, Auulicino T, Gombert ME, Snyder R. Penetration of topically applied ciprofloxacin, norfloxacin, and ofloxacin into the aqueous humor. Ophthalmology. 1994;101(5):902-905
13. Kunimoto DY, Sharma S, Garg P, Rao GN. In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin. Emerging resistance. Ophthalmology. 1999;106(1):80-85
14. Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133(4):463-466
15. Kowalski RP, Karenchak LM, Romanowski EG, Mah FS, Ritterband DC, Gordon YJ. Will the fourth-generation fluoroquinolones provide any advantage in the future treatment of bacterial keratitis? In: 36th Annual Meeting: Ocular Microbiology and Immunology Group (OMIG); 2002; Orlando, FL; 2002. Available from: http://eyemicrobiology.upmc.com/2002Abstracts/2002Abs1.htm
16. Monica M, Jensen HG. Susceptibility of ocular isolated to gatifloxacin and other fluoroquinolones. In: 36th Annual Meeting: Ocular Microbiology and Immunology Group (OMIG); 2002; Orlando, FL; 2002. Available from: http://eyemicrobiology.upmc.com/2002Abstracts/2002Abs3.htm
17. Hariprasad SM, Mieler WF, Holz ER. Vitreous and aqueous penetration of orally administered gatifloxacin in humans. Arch Ophthalmol. 2003;121(3):345-350
18. Garcia-Saenz MC, Arias-Puente A, Fresnadillo-Martinez MJ, arrasco-Font C. Human aqueous humor levels of oral ciprofloxacin, levofloxacin, and moxifloxacin. J Cataract Refract Surg. 2001;27(12):1969-1974
19. Balfour JA, Wiseman LR. Moxifloxacin. Drugs. 1999;57(3):363-73; discussion p.374.
20. Shah M, Ritterband DC, Dingley A, Koplin R, Seedor J. Will the new generation of fluoroquinolone antibiotics become the antimicrobials of choice in endophthalmitis prophylaxis? In: 36th Annual Meeting: Ocular Microbiology and Immunology Group (OMIG); 2002; Orlando, FL; 2002. Available from: http://eyemicrobiology.upmc.com/2002Abstracts/2002Abs12.htm
21. Myung-Jin J, Aliprandis E, Terrence P, O'Brien TP. Comparative efficacy of topical gatifloxacin, a new fluoroquinolone, versus topical ciprofloxacin, penicillin G and tobramycin in the treatment of experimental S. pneumoniae and P. aeruginosa keratitis in rabbits. In: 36th Annual Meeting: Ocular Microbiology and Immunology Group (OMIG); 2002; Orlando, FL; 2002. Available from: http://eyemicrobiology.upmc.com/2002Abstracts/2002Abs2.htm
22. NCCL. Methods for dilution antimicrobials susceptibility tests for bacteria that grow aerobically. Villanova, Pennsylvania: National Committee for Clinical Laboratory Standards; 2000.
23. Ednie LM, Jacobs MR, Appelbaum PC. Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms. Antimicrob Agents Chemother. 1998;42(9):2459-2462